Business Context and Reporting Period
This Form 8-K is filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on January 25, 2021. The report addresses a regulatory matter regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with Nasdaq listing rules.
Material Changes
- Regulatory Status: The Company previously received a deficiency notice on September 24, 2020, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- Compliance Regained: On January 22, 2021, Nasdaq confirmed the Company regained compliance with Listing Rule 5550(a)(2). The stock maintained a closing bid price of $1.00 or greater for 11 consecutive business days (January 6 through January 22, 2021).
- Outcome: Nasdaq considers the delisting matter closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The primary risk addressed was the potential delisting due to low stock price, which has been resolved as of the report date.
Investor Verification Checklist
- Verify the current trading symbol is AIKI on The Nasdaq Stock Market LLC.
- Confirm the stock price has remained above the $1.00 threshold following the January 22, 2021 compliance date.
- Note that the registrant name in the filing is Aikido Pharma Inc., distinct from the metadata field "Dominari Holdings Inc."
- Review the attached press release (Exhibit 99.1) for any additional details on the compliance restoration.